Nitroglycerin

Where It Comes From

Nitroglycerin was first synthesized by Italian chemist Ascanio Sobrero in 1847 as a yellowish oily liquid with explosive properties [1]. Swedish engineer Alfred Nobel discovered its desensitization by mixing with kieselguhr in 1867, creating dynamite, which revolutionized mining, construction, and warfare. This innovation earned Nobel his fortune and later inspired the Nobel Prize. Simultaneously, physicians discovered nitroglycerin's therapeutic properties for angina pectoris in the 1870s, with William Murrell establishing its clinical use [2]. Today, nitroglycerin remains a critical cardiovascular medication while also being used in commercial blasting operations and military explosives. The compound exemplifies the dual-use nature of chemistry—the same molecule that saves cardiac patients also fuels industrial explosives and weapons [3].

How You Are Exposed

Occupational exposure occurs primarily in explosives manufacturing, mining, construction, and military ordnance production. Workers handling nitroglycerin-containing explosives face skin contact and inhalation risks. Occupational exposure causes distinctive health effects including headaches and hemodynamic tolerance. Medical patients taking nitroglycerin pharmaceuticals have controlled therapeutic exposure. Accidental contamination can occur around blasting sites.

Why It Matters

Occupational exposure to nitroglycerin causes characteristic 'Monday morning headaches' due to sudden vasodilation and increased intracranial pressure. Workers develop tolerance during the work week and experience rebound hypertension on days off, causing severe headaches. Chronic exposure increases cardiovascular disease risk. Nitroglycerin causes methemoglobinemia at high doses, potentially impairing oxygen transport and causing cyanosis.

Who Is at Risk

Explosives manufacturing workers, miners, demolition specialists, and military ordnance handlers face occupational risk. Workers with cardiovascular disease are more vulnerable to hemodynamic effects. Individuals with methemoglobin reductase deficiency are at increased risk of methemoglobinemia. Communities near blasting operations may experience environmental exposure.

Recovery & Clinical Information

Body Half-Life

Nitroglycerin is rapidly absorbed through mucous membranes and skin, metabolized by hepatic glutathione-dependent nitrate reductase enzymes. The half-life is approximately 1-3 minutes due to rapid metabolism and distribution. Metabolites are eliminated primarily through urine. The brief half-life explains why pharmaceutical nitroglycerin requires multiple doses daily.

Testing & Biomarkers

Exposure to nitroglycerin is detected through occupational air and surface monitoring. Biological monitoring includes methemoglobin levels and carboxyhemoglobin assessment. Clinical evaluation focuses on cardiovascular function tests and blood pressure monitoring. Workers are screened for tolerance development through baseline and periodic cardiovascular assessment.

Interventions

Acute exposure management includes removal from exposure and supportive care for headaches and hemodynamic effects. Methemoglobinemia treatment involves methylene blue if levels exceed 20%. Long-term management focuses on cardiovascular monitoring and rotation away from high-exposure areas. Tolerance management includes scheduled breaks from exposure.

Recovery Timeline

Acute symptoms (headaches) appear within 4-6 hours of initial exposure or after days off. Tolerance develops over days to weeks with continuous exposure. Withdrawal symptoms appear within 24-48 hours of exposure cessation. Long-term occupational disease effects develop over years of chronic exposure.

Recovery References

[1][1] Sobrero, A. (1847). 'On the Compounds of Glycerin with the Acids.' Giornale di Scienze Naturali e di Industria, 1, 288-294.
[2][2] Murrell, W. (1879). 'Nitroglycerin as a Remedy for Angina Pectoris.' The Lancet, 1(4067), 80-81.
[3][3] ATSDR (2005). 'Toxicological Profile for Nitroglycerin.' Agency for Toxic Substances and Disease Registry.